טוען...
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
The objective of this study was to evaluate the efficacy and safety profile of weekly docetaxel, estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer. Forty-eight patients received 35 mg m(−2) of weekly docetaxel for 3 out of every 4 weeks, 280 mg of estramustine t...
שמור ב:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group
2007
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2360463/ https://ncbi.nlm.nih.gov/pubmed/17955053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604030 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|